Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05040685
Other study ID # PR139/21
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2021
Est. completion date July 1, 2023

Study information

Verified date February 2024
Source Hospital Universitari de Bellvitge
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The axillary mapping reverse (ARM) consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema. A significant decrease of lymphedema rates in patients who was possible associate ARM technique during the axillary surgery improving the quality of life of these patients. There are different visualisation techniques like fluorescence dye.


Description:

Axillary lymph node dissection (ALND) was the standard therapy until 1990-2000, when the technique was replaced, when possible, by another procedure associated with less morbidity: the sentinel lymph node biopsy (SLNB). However, actually, ALND is still the gold standard in some patients. This procedure is associated with substantial morbidity, like lymphedema, shoulder pain, arm numbness, axillary web syndrome and decreased upper-extremity range of motion (ROM), that severely conditions the quality of life of these patients. In 2007, the investigators had the first reports about a new surgical technique, the axillary mapping reverse (ARM), that consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema. The current literature shows a significant decrease of lymphedema rates in patients who was possible associate this technique during the axillary surgery improving the quality of life of these patients. There are different visualisation techniques. With the use of indocyanine green, the visualisation rates in the axilla of ARM lymphatics are from 88%, similar to other techniques. Some advantages of fluorescence dye are that no systemic allergic reactions have been reported and the 'green tattoo' disappears quickly. HYPHOTESIS The axillary mapping reverse (AMR) is able to identify the lymph nodes responsible for lymphatic drainage of the ipsilateral upper limb (ARM nodes) in breast cancer patients who underwent an axillar lymph node dissection.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date July 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients who will undergo ALND in the treatment of breast cancer: - cT4a, cT4c and cT4d. - cT4b with extensive involvement of the skin. - cN0 with SLNB positive (pN+) that need to associate ALND: - cT3-T4b. - >2 lymph node macrometastasis if cTis, cT1 and cT2. - Patients who underwent mastectomy and it is not possible associate adjuvant radiotherapy. - cN1: - If primary surgery treatment. - After neoadjuvant systemic treatment, if there is not a clinical-radiological complete response and/or SLNB positive (ypN+). - cN2: - If primary surgery treatment. - After neoadjuvant systemic treatment, if luminal tumours or there is not a clinical-radiological complete response in triple negative or HER2 overexpressed tumours. - cN3. Exclusion Criteria: - Patients with previous axillary surgery (except sentinel node biopsy) - Patients who did previous axillary radiotherapy treatment. - Patients who do not wish to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Axillary mapping reverse
At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.

Locations

Country Name City State
Spain Hospital de Bellvitge Hospitalet de Llobregat Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitari de Bellvitge

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of patients who it is possible preserve ARM nodes Determinate the percentage of patients who is possible preserve the ARM node during ALND 1 year
Secondary Rate of metastatic ARM Determinate the percentage of metastatic ARM nodes. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05873621 - Indocyanine Green-guided Lymphadenectomy in Laparoscopic Total Mesorectal Excision for Low Rectal Cancer After Neoadjuvant Chemoradiotherapy N/A
Active, not recruiting NCT02570399 - High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients N/A